Three years ago, Lilly gambled big on managed care with its acquisition of PCS--and lost. Its new strategy wagers almost as much on research, but this time the bets are hedged. As it aggressively builds infrastructure, it expands its program but limits its own flexibility and diminishes the likelihood that it can exploit all of its programs. Thus it will increasingly outlicense and sell assets it is not exploiting.
You may also be interested in...
Lilly's co-promotion with Boehringer Ingelheim of duloxetine is the first time the American company has signed a major marketing deal for one of its own products. The company notes the collaboration is part of its broad commitment to partnering and that the market is intensely competitive. But the choice of duloxetine--the launch of which may be delayed indefinitely because of manufacturing problems--also represents Lilly's lowest-risk option for subsidizing the launches, and maximizing the returns from, potentially eight new products over the next few years.
The Personal Care Products Council and other industry groups suggest they will support AB 2771 if amendments are made to promote international harmonization, among other changes. Already they advocated successfully for the bill’s scope to be limited to intentionally added PFAS, not “the mere presence of trace levels of fluorine in the product.”
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.